Impact of HIV and Its Treatment on Reverse Cholesterol Transport

Impact of HIV Infection and Treatment With Highly Active Antiretroviral Therapy on Reverse Cholesterol Transport

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00168233

Enrollment

Registered

2005-09-15

Start date

2005-06-30

Completion date

2011-03-31

Last updated

2012-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Treatment Naive, HIV

Brief summary

To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness in HIV patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male patients with HIV infection (3 groups of 50 patients each) * HIV infected patients, naïve to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months) * HIV-infected patients, PI naïve, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen) * HIV-infected patients naïve to ARV therapy, initiating NNRTI-containing regimen

Exclusion criteria

* Treatment with any form of lipid lowering drugs, including fish oils. * Body Mass Index greater than 27.

Countries

Australia

Outcome results